Developed by Novo Nordisk , Victoza was given US FDA approval in January 2010
*Correspondence: Xian-Feng Zhang, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Castilla EE, da Graca Dutra M, Orioli-Parreiras IM
It typically develops quickly and appears as pus filled blisters
Updated May 23 2019
Unlike many peptides that are studied within a single research niche, BPC-157 has been examined across gastrointestinal, musculoskeletal, vascular, dermal, and neurological tissue models suggesting a broad influence on fundamental repair and regeneration mechanisms that operate across multiple tissue types